BIOMAT Database Logo BIOMAT Database Logo

Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. 2008

A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Service de Pneumologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.

BACKGROUND Birch pollen and pollen from related trees of the Fagales order are a major cause of allergic rhinitis, conjunctivitis, and asthma through the spring season in northern and central Europe. OBJECTIVE To investigate the clinical effects of injection immunotherapy with genetically modified derivatives of major birch pollen allergen Bet v 1 on pollen-induced allergic symptoms. METHODS A three-arm double-blind placebo-controlled immunotherapy study was conducted with one pre-seasonal course of treatment using two derivatives of Bet v 1, namely a recombinant Bet v 1 trimer and an equimolar mixture of two recombinant Bet v 1 fragments together representing the whole protein sequence. Analysis of local and systemic adverse events was performed for 124 patients who had received at least one dose of medication. Clinical efficacy was monitored by symptom medication scores and interval scoring in the per protocol-treated population (n=84). In addition, skin and nasal provocation responses and allergen-specific antibodies were assessed. RESULTS There were trends towards improvement in the subjects' well-being and clinical symptoms (nasal scores), although comparisons with a placebo group did not show statistical significance in the main end-point, the combined symptom medication score. Reductions in skin and nasal sensitivity were observed for some subjects with a trend for the Bet v 1 trimer to be more effective than the fragments. Treatment induced strong IgG1 and IgG4 allergen-specific antibody responses. Local injection-site reactions were most frequent in the trimer group affecting 59.5% of patients as opposed to 37.8% and 30.6% in the fragment and placebo groups, respectively. Systemic reactions were elicited more frequently by fragments. A large proportion of adverse side-effects appeared hours following injections, and might be attributable to concurrent exposure to related pollens. CONCLUSIONS Single courses of injection immunotherapy with Bet v 1 allergen derivatives showed trends towards improved well-being and reduced reactivity to specific allergen provocation, but did not yield significant improvement in the combined symptom medication score in this study.

UI MeSH Term Description Entries
D006967 Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011058 Pollen The fertilizing element of plants that contains the male GAMETOPHYTES. Male Gametes, Plant,Male Gametophytes,Microspores, Plant,Plant Microspores,Pollen Grains,Gamete, Plant Male,Gametes, Plant Male,Gametophyte, Male,Gametophytes, Male,Grain, Pollen,Grains, Pollen,Male Gamete, Plant,Male Gametophyte,Microspore, Plant,Plant Male Gamete,Plant Male Gametes,Plant Microspore,Pollen Grain
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003888 Desensitization, Immunologic Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity. Allergen Immunotherapy,Allergy Shots,Hyposensitization Therapy,Immunotherapy, Allergen,Venom Immunotherapy,Immunologic Desensitization,Therapy, Hyposensitization,Allergen Immunotherapies,Allergy Shot,Desensitizations, Immunologic,Hyposensitization Therapies,Immunologic Desensitizations,Immunotherapy, Venom,Shot, Allergy,Venom Immunotherapies
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females

Related Publications

A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
January 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
November 1999, The Journal of allergy and clinical immunology,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Characterisation of recombinant isoforms of birch pollen allergen Bet v 1.
January 1996, Advances in experimental medicine and biology,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients.
July 2000, The Journal of allergy and clinical immunology,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen.
December 2010, Human vaccines,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Recombinant birch allergens (Bet v 1 and Bet v 2) and the oral allergy syndrome in patients allergic to birch pollen.
November 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy.
January 1999, International archives of allergy and immunology,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch].
September 1996, Pneumologie (Stuttgart, Germany),
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2.
January 1996, The Journal of allergy and clinical immunology,
A Purohit, and V Niederberger, and M Kronqvist, and F Horak, and R Grönneberg, and R Suck, and B Weber, and H Fiebig, and M van Hage, and G Pauli, and R Valenta, and O Cromwell
Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen.
January 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Copied contents to your clipboard!